GlaxoSmithKline: US FDA Advisory Committee Votes To Support Effectiveness And Safety Of GSK's Respiratory Syncytial Virus Older Adult Vaccine Candidate
March 02, 2023
March 02, 2023
LONDON, England, March 2 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release:
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the available data support the safety and effectiveness of GSK's respiratory syncytial virus (RSV) older adult vaccine candidate for the prevention of lower respiratory tract disease (LRTD) caused by RSV in . . .
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the available data support the safety and effectiveness of GSK's respiratory syncytial virus (RSV) older adult vaccine candidate for the prevention of lower respiratory tract disease (LRTD) caused by RSV in . . .